Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3

Translational and Clinical Outcomes

1st Edition - April 15, 2022
Editors: Ganji Purnachandra Nagaraju, Sarfraz Ahmad
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 9 9 2 8 3 - 1
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 9 2 8 4 - 8

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma: Translational and Clinical Outcomes, Volume Three provides comprehensive information about ong… Read more

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma: Translational and Clinical Outcomes, Volume Three provides comprehensive information about ongoing research and clinical data on liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. This updated volume discusses topics such as clinical and safety assessment of HCC patients, liver transplantation as a therapeutic option, immunotherapy interventions, and image-based surveillance. In addition, it discusses immunohistology of HCC-enabled precision medicine and artificial intelligence for hepatocellular carcinomas.

This is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.

Cover image
Title page
Table of Contents
Copyright
Dedication
List of contributors
About the editors
Preface
Chapter 1. Nanoparticles for diagnosis and treatment of hepatocellular carcinoma
Abstract
Abbreviations
Introduction
Chitosan nanoparticles
Mesoporous silica nanoparticles
Iron oxide nanoparticles
Liposomal nanoparticles
Solid lipid nanoparticles
Gold nanoparticles
Titanium oxide nanoparticles
Pectin-based nanoparticles
mPEG-PLGA-PLL copolymer-based nanoparticles
Nanoparticles in clinical trials to treat hepatocellular carcinoma
Toxicity
Conclusion
References
Chapter 2. Theranostics application of nanocarriers in hepatocellular carcinoma
Abstract
Abbreviations
Introduction
Conclusion
Acknowledgment
Conflict of interest
References
Chapter 3. Nanoparticle-based theranostics and their role in hepatocellular carcinoma
Abstract
Abbreviations
Introduction
Pathogenesis
Nanotheranostics in hepatocellular carcinoma
Conclusions and future perspectives
Conflicts of interest
References
Chapter 4. Therapeutic options for the management of hepatocellular carcinoma
Abstract
Abbreviations
Introduction
Chemotherapeutic drugs
Immunotherapy
Phytochemicals
Nanomedicines
Conclusion
References
Chapter 5. Targeting hepatocellular carcinoma by small-molecule inhibitors
Abstract
Abbreviations
Introduction
Small-molecule inhibitors and their relevance in cancer
Conclusion
Acknowledgment
Conflict of interest
Funding
References
Chapter 6. Curing of liver cancer: an update on the efficacy of bioactive compounds
Abstract
Abbreviations
Background study of liver cancer
Introduction
Conclusion and future perspectives
Conflict of interest
References
Chapter 7. Plant therapeutics for hepatocellular carcinoma
Abstract
Abbreviations
Introduction
Biology of liver
Histopathology of liver
Liver cancer risk factors and diagnosis
Natural compounds on liver cancer
Conclusion and future outlook
Acknowledgments
Conflict of interest
References
Chapter 8. Phytochemicals for hepatocellular carcinoma therapy: from in vitro to clinic
Abstract
Abbreviations
Introduction
Genes associated with hepatocellular carcinoma
Genes involved in WNT- and TGF-β-signaling cascade
Herbs and their secondary metabolites
Conclusion
Conflict of interest
References
Chapter 9. Resveratrol for hepatocellular carcinoma therapy
Abstract
Abbreviations
Introduction
Structure
Source
Chemical synthesis
Functions of resveratrol
Resveratrol as a phytoalexin
Resveratrol as a natural phenol
Resveratrol as a natural antioxidant
Resveratrol as anticarcinogenic agent
Reactive oxygen species
Role of resveratrol on hepatocellular carcinoma (liver cancer)
Conclusions and future perspectives
Conflict of interest
References
Chapter 10. Curcumin: a spice pigment against hepatic cancer
Abstract
Abbreviations
Introduction
Curcumin: the golden spice component
Biological activity of curcumin
Curcumin and liver cancer
Limitations and prospects
Conclusion
Acknowledgments
Declarations of interest
Funding
References
Chapter 11. Curcumin formulated nanoparticles for hepatocellular carcinoma
Abstract
Abbreviations
Introduction
Chemicals involved in hepatocellular carcinoma
Curcumin nanoformulations in hepatocellular carcinoma
Synthesis of nanoformulations
Anticancer properties of curcumin facilitated nanoformulations
Conclusion
Funding
Conflict of interest
References
Chapter 12. Role of phytoconstituents in the hepatocellular carcinoma management: current perspective, challenges, and future perspectives
Abstract
Abbreviations
Introduction
References
Chapter 13. Phytonanoformulations for hepatocellular carcinoma therapy
Abstract
Abbreviations
Introduction
Nanomedicine
Properties of nanoparticles
Nanophytochemicals used in cancer treatment
Phytochemicals used in the treatment of hepatocellular carcinoma
Conclusion
References
Chapter 14. Immune checkpoint inhibitors for hepatocellular carcinoma
Abstract
Abbreviations
Introduction
The immunology of hepatocellular carcinoma
Immune responses of the liver that promotes tumor cell proliferation
Immune checkpoint inhibitors and hepatocellular carcinoma
Combination immunotherapy: potential treatment of the future?
Conclusion and future perspective
Acknowledgments
References
Chapter 15. Recent advancements in immunotherapy interventions for the management of liver cancer
Abstract
Abbreviations
Introduction
Types of immunotherapy
Advantages and disadvantages
Future direction and conclusion
References
Chapter 16. Immunotherapy for hepatocellular cancer: a review of current status
Abstract
Abbreviations
Introduction
Hepatocellular carcinoma immunology
Immune checkpoint inhibitors
Checkpoint inhibitors for hepatocellular carcinoma monotherapy
Combination treatment
Conclusions and future perspective
References
Chapter 17. Updates on clinical trials for the management of hepatocellular carcinoma
Abstract
Abbreviations
Introduction
Staging and prognosis in hepatocellular carcinoma
Management of hepatocellular carcinoma
Second-line systemic therapies
Conclusions and future perspectives
References
Chapter 18. Theranostic and precision medicine for the diagnosis of hepatocellular carcinoma
Abstract
Abbreviations
Epidemiology
Ultrasound
Computed tomography
Magnetic resonance imaging
Tumor markers
Guidelines for hepatocellular carcinoma surveillance
Cost-effectiveness of hepatocellular carcinoma diagnostic modalities
Conflict of interest
References
Chapter 19. Precision medicine approaches for treating hepatocellular carcinoma
Abstract
Abbreviations
General information on hepatocellular carcinoma
Ablation
Embolization
Precision medicine definition and use in cancers in general
Significance for using precision medicine approaches for treating hepatocellular carcinoma
Chemo-resistive mechanisms in hepatocellular carcinoma
Liquid biopsy
Summary and conclusions
Future directions
Acknowledgments
References
Chapter 20. Decoding the functional role of extracellular vesicles in hepatocellular carcinoma: implications in clinical theranostics
Abstract
Abbreviations
Functional role of EVs in hepatocellular carcinoma: from angiogenesis to metastatic organotropism
EVs in targeted therapeutic interventions in HCC
Conclusion and future prospects
Conflict of interest
Funding
References
Chapter 21. Cathepsin B: structure, function, tumorigenesis, and prognostic value in hepatocellular carcinoma
Abstract
Abbreviations
Introduction
Structure-function properties of cathepsin B
Tumorigenesis and metastatic role of cathepsin B in cancers with emphasis on hepatocellular carcinoma
Prognostic values of cathepsin B in hepatocellular carcinoma
Conclusions and future perspective
Conflict of interest
References
Chapter 22. Chemotherapy for hepatocellular carcinoma—an updated review
Abstract
Abbreviations
Introduction
Risk factors and pathogenesis of hepatocellular carcinoma
Chemotherapy for hepatocellular carcinoma
Sorafenib–a first-line chemotherapeutic agent
Immunotherapeutic agents
Conclusion
Conflict of interest
References
Chapter 23. Recent advances in medical treatment of hepatocellular cancer
Abstract
Abbreviations
Introduction
Lenvatinib
Regorafenib
Cabozantinib
Ramucirumab
Bevacizumab plus atezolizumab
Nivolumab and nivolumab plus ipilimumab
Nivolumab plus ipilimumab
Pembrolizumab
Sequencing systemic in advanced hepatocellular carcinoma
Conclusions and future perspectives
References
Chapter 24. Recent perspectives on therapeutic significance of microRNAs in hepatocellular carcinoma
Abstract
Abbreviations
Introduction
Conclusions
Acknowledgment
References
Chapter 25. Pharmacogenomics and outcomes for hepatocellular cancer treatment
Abstract
Abbreviations
Introduction
Pathophysiological aspects
Guidelines for treatment of hepatocellular carcinoma
Challenges in treatment of hepatocellular carcinoma
Pharmacogenomic considerations for hepatocellular carcinoma treatments
References
Chapter 26. Epigenetic biomarkers in diagnosis, prognosis, and treatment of hepatocellular carcinoma
Abstract
Abbreviations
Introduction
DNA methylation in hepatocellular carcinoma
Histone modifications in hepatocellular carcinoma
Conclusion
Conflict of interest
References
Index

Ganji Purnachandra Nagaraju

Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books in Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).

Affiliations and expertise

Assistant Professor, School of Medicine, Division of Hematology and Oncology, University of Alabama, Birmingham, AL, United States.

Sarfraz Ahmad

Prof. Ahmad S is Director of Clinical Research at AdventHealth Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD in Biochemistry from North-Eastern Hill University, Shillong. Prof. Ahmad’s research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology, hematology, and gastroenterology (GI) patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic/hematologic disorders. Prof. Ahmad has published over 250 peer-reviewed scholarly research articles and book chapters, and over 400 scientific abstracts. He is a reviewer and has editorial responsibilities for several biomedical journals and books; and has received competitive research grants and national/international awards for his research contributions/accomplishments

Affiliations and expertise

University of Alabama, Birmingham, AL, USA.